Jean-Louis Corhay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean-Louis Corhay has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anne Sibille
Department of Pulmonology, University Hospital of Liège, Liège, Belgium
1 shared publication - Bernard Duysinx
Department of Respiratory Medicine, University Hospital (CHU) of Liège, 4000 Liège, Belgium
1 shared publication - Guy Jerusalem
CHU Liège and Liège University, Liège, Belgium
1 shared publication - Renaud Louis
Respiratory Department University Hospital of Liège Liège Belgium
1 shared publication - Vincent Ninane
Department of Pneumology, Centre Hospitalier Universitaire St Pierre & Brugmann, 1000 Bruxelles, Belgium
1 shared publication
Latest Publications
- Open Access
- 3 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5066
Eosinophils and Lung Cancer: From Bench to Bedside
Eosinophils are rare, multifunctional granulocytes. Their growth, survival, and tissue migration mainly depend on interleukin (IL)-5 in physiological conditions and on IL-5 and IL-33 in inflammatory conditions. Preclinical evidence supports an immunological role for eosinophils as innate immune cells and as agents of the adaptive immune response. In addition to these data, several reports show a link between the outcomes of patients treated with immune checkpoint inhibitors (ICI) for advanced cancers and blood eosinophilia. In this review, we present, in the context of non-small cell lung cancer (NSCLC), the biological properties of eosinophils and their roles in homeostatic and pathological conditions, with a focus on their pro- and anti-tumorigenic effects. We examine the possible explanations for blood eosinophilia during NSCLC treatment with ICI. In particular, we discuss the value of eosinophils as a potential prognostic and predictive biomarker, highlighting the need for stronger clinical data. Finally, we conclude with perspectives on clinical and translational research topics on this subject.
- 3 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (9) , 5066
Open AccessEosinophils and Lung Cancer: From Bench to Bedside
Eosinophils are rare, multifunctional granulocytes. Their growth, survival, and tissue migration mainly depend on interleukin (IL)-5 in physiological conditions and on IL-5 and IL-33 in inflammatory conditions. Preclinical evidence supports an immunological role for eosinophils as innate immune cells and as agents of the adaptive immune response. In addition to these data, several reports show a link between the outcomes of patients treated with immune checkpoint inhibitors (ICI) for advanced cancers and blood eosinophilia. In this review, we present, in the context of non-small cell lung cancer (NSCLC), the biological properties of eosinophils and their roles in homeostatic and pathological conditions, with a focus on their pro- and anti-tumorigenic effects. We examine the possible explanations for blood eosinophilia during NSCLC treatment with ICI. In particular, we discuss the value of eosinophils as a potential prognostic and predictive biomarker, highlighting the need for stronger clinical data. Finally, we conclude with perspectives on clinical and translational research topics on this subject.